Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An...

Area of Science:

• Pharmacology
• Immunology
• Drug Development

Background:

• Ritlecitinib is an investigational small molecule designed for covalent and irreversible inhibition of Janus kinase 3 (JAK3) and the TEC family of kinases.
• Understanding the target occupancy and functional effects of ritlecitinib is crucial for its clinical development.

Purpose of the Study:

• To assess the target occupancy and functional effects of single doses of ritlecitinib on JAK3 and TEC family kinases in healthy adults.
• To evaluate the dose-proportionality of ritlecitinib plasma exposure.

Main Methods:

• Phase 1, open-label, parallel-group study involving healthy participants aged 18-60 years.
• Administration of single oral doses of 50 mg or 200 mg ritlecitinib.
• Assessment of pharmacokinetics, target occupancy (mass spectroscopy), and pharmacodynamics (pSTAT5 inhibition for JAK3, CD69 upregulation for BTK) over 48 hours.

Main Results:

• Ritlecitinib plasma exposure increased approximately dose-proportionally from 50 mg to 200 mg.
• Maximal median JAK3 target occupancy ranged from 64% to 72%, with high TEC family kinase occupancy (>94% for 50 mg, >97% for 200 mg).
• Ritlecitinib demonstrated dose-dependent reduction in pSTAT5 and CD69, indicating functional inhibition of JAK3 and BTK pathways.

Conclusions:

• Single doses of ritlecitinib achieve significant target occupancy and functional inhibition of both JAK3 and TEC family kinases, including Bruton's tyrosine kinase (BTK).
• The findings support the dual inhibition mechanism of ritlecitinib.
• Further investigation is warranted to correlate these pharmacodynamic effects with clinical outcomes.